FluoGuide A/S (STO:FLUO)
Sweden · Delayed Price · Currency is SEK 42.40
+1.50 (3.67%)
May 4, 2026, 5:22 PM CET
FluoGuide Earnings Call Transcripts
Fiscal Year 2025
-
Three positive Phase II trials, new partnerships, and a strengthened management team marked a pivotal year, with a net loss of DKK 39 million and a strong cash position. Regulatory progress with the FDA and upcoming clinical milestones set the stage for further growth.
-
A novel imaging agent enables surgeons to better identify and remove cancer during surgery, with proven efficacy in multiple cancer types and strong FDA feedback. Market entry is prioritized in the U.S. with broad equipment compatibility and strategic partnerships.